Stocktwits on MSN

KZIA stock is rising today — what does its data for nuclear PD-L1 degrader show?

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...
The Pharma Letter

Kazia advances nuclear PD-L1 degrader with preclinical data

Australian oncology-focused biotech Kazia Therapeutics (Nasdaq: KZIA) has reported preclinical and translational data supporting NDL2, a protein degrader designed to eliminate nuclear PD-L1, an ...
Targeted Oncology

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
Nasdaq

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
The American Journal of Managed Care

Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
Seeking Alpha

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
FiercePharma

On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...